Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 2, 1999, Pages 849-857

  Mizushima, Yuko ^a   Amano, Yukio ^a   Kitagawa, Hiroshi ^a   Ogata, Kenji ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROOROTATE DEHYDROGENASE; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; LEFLUNOMIDE; OVALBUMIN; TERIFLUNOMIDE;

ANAPHYLACTIC SHOCK; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOREGULATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS;

ADMINISTRATION, ORAL; ANILINE COMPOUNDS; ANIMALS; ANTIBODY SPECIFICITY; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HYDROXYBUTYRATES; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LYMPHOCYTE ACTIVATION; OVALBUMIN; RATS; RATS, INBRED BN; URIDINE;

EID: 0033058631     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bartlett RR, Dimitrijevic M, Mattar T, Zielinski T, Germann T, Rüde E, Thoenes GH, Küchle CCA, Schorlemmer HU, Bremer E, Finnegan A and Schleyerbach R (1991) Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 32:10-21.
2. Bartlett RR, Mattar T, Weithmann U, Anagnostopoulos H, Popovic S and Schleyerbach R (1989) Leflunomide (HWA 486): A novel immunorestoring drug, in Therapeutic Approaches to Inflammatory Diseases (Lewis AJ, Doherty NS and Ackerman NR eds) pp 215-228, Elsevier Science Publishing, New York.
3. Bartlett RR, Popovic S and Raiss RX (1988) Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease. Scand J Rheumatol Suppl 75:290-299.
4. Bartlett RR and Schleyerbach R (1985) Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity-I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 7:7-18.
5. Chong ASF, Rezai K, Gebel HM, Finnegan A, Foster P, Xu XL and Williams JW (1996) Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 61:140-145.
6. Kopf M, Gros GL, Bachmann M, Lamers MC, Bluethmann H and Köhler G (1993) Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature (Lond) 362:245-248.
7. Küchle CCA, Thoenes GH, Langer KH, Schorlemmer HU, Bartlett RR and Schleyerbach R (1991) Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc 23:1083-1086.
8. Mattar T, Kochhar K, Bartlett R, Bremer EG and Finnegan A (1993) Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 334:161-164.
9. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M, Dimitrijevic M, Zivkovic M, Campion G, Musikic P, Löw-Friedrich I, Oed C, Seifert H and Strand V (1995) Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis & Rheum 38:1595-1603.
10. Mrowka C, Thoenes GH, Langer KH and Bartlett RR (1994) Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomide. Ann Hematol 68:195-199.
11. Popovic S and Bartlett RR (1987) The use of the murine chronic graft Vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents Actions 21:284-286.
12. Rebbaa A, Hurh J, Yamamoto H, Kersey DS and Bremer EG (1996) Ganglioside GM3 inhibition of EGF receptor mediated signal transduction. Glycobiology 6:399-406.
13. Schorlemmer HU and Bartlett RR (1994) Therapeutic activity of leflunomide in acute and chronic relapsing experimental allergic encephalomyelitis. Agents Actions 41:C271-C273.
14. Schorlemmer HU, Seiler FR and Bartlett RR (1993) Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative. Transplant Proc 25:763-767.
15. Siemasko KF, Chong ASF, Williams JW, Bremer EG and Finnegan A (1996) Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 61:635-642.
16. Silva HT, Shorthouse R and Morris RE (1996) Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats. Transplant Proc 28:3092-3094.
17. Solbach W, Asmuß PA, Zimmermann S, Humborg C and Röllinghoff M (1995) Protective effect of leflunomide on the natural course of Leishmania major-induced disease in genetically susceptible BALB/c mice. Int J Immunopharmacol 17:481-488.
18. Thoenes GH, Sitter T, Langer KH, Bartlett RR and Schleyerbach R (1989) Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int J Immunopharmacol 11:921-929.
19. Williamson RA, Yea CM, Robson PA, Curnock AP, Gadher S, Hambleton AB, Woodward K, Bruneau JM, Hambleton P, Moss D, Thomson TA, Spinella-Jaegle S, Morand P, Courtin O, Sautés C, Westwood R, Hercend T, Kuo EA and Ruuth E (1995) Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 270:22467-22472.
20. Xu X, Williams JW, Bremer EG, Finnegan A and Chong AS-F (1995) Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 270:12398-12403
21. Xu X, Williams JW, Gong H, Finnegan A and Chong AS-F (1996) Two activities of the immunosuppressive metabolite of leflunomide, A77 1726: Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol 52:527-534.
22. Zielinski T, Zeitter D, Müllner S and Bartlett RR (1995) Leflunomide, a reversible inhibitor of pyrimidine biosynthesis? Inflamm Res 44(Suppl 2):S207-S208.